<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01336166</url>
  </required_header>
  <id_info>
    <org_study_id>SIBP-2009</org_study_id>
    <nct_id>NCT01336166</nct_id>
  </id_info>
  <brief_title>The Long-term Immunogenicity of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Institute Of Biological Products</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Institute Of Biological Products</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the long-term immunogenicity and safety of the
      inactivated split-virion vaccine after one immunization.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemagglutination inhibition antibody titer</measure>
    <time_frame>Day 180</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>occurrence of solicited local and systemic adverse events after vaccination</measure>
    <time_frame>Days 0-42</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">480</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>split-virion, non-adjuvanted vaccine of 15 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>split-virion, non-adjuvanted H1N1 vaccine of 15 μg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>split-virion, non-adjuvanted vaccine of 30 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>split-virion, non-adjuvanted H1N1 vaccine of 30 μg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>split-virion, non-adjuvanted vaccine of 45 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>split-virion, non-adjuvanted H1N1 vaccine of 45 μg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>split-virion, non-adjuvanted H1N1 vaccine of 15 μg</intervention_name>
    <description>120 adults were assigned to receive 1 dose of 15μg split-virion, non-adjuvanted H1N1 vaccine.</description>
    <arm_group_label>split-virion, non-adjuvanted vaccine of 15 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>split-virion, non-adjuvanted H1N1 vaccine of 30 μg</intervention_name>
    <description>120 adults were assigned to receive 1 dose of 30μg split-virion, non-adjuvanted H1N1 vaccine.</description>
    <arm_group_label>split-virion, non-adjuvanted vaccine of 30 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>split-virion, non-adjuvanted H1N1 vaccine of 45 μg</intervention_name>
    <description>120 adults were assigned to receive 1 dose of 45μg split-virion, non-adjuvanted H1N1 vaccine.</description>
    <arm_group_label>split-virion, non-adjuvanted vaccine of 45 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo control</intervention_name>
    <description>120 adults were assigned to receive 1 dose of placebo.</description>
    <arm_group_label>Placebo control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Different age groups from 18 to 60 years, with normal intelligence and health.
             Volunteers (or their guardians) are well informed of the situation and sign the
             consent

          2. Vaccination recipients qualified for this product have been inquired about medical
             history and clinically proven to be healthy

          3. Requests of clinical research program can be obeyed

          4. No other protective product is inoculated in last week

          5. Axillary temperature below 37 degrees Celsius

        Exclusion Criteria:

          1. Volunteers in another clinical trial investigating a vaccine, drug, medical device, or
             medical procedure in the 4 weeks preceding the first trial vaccination

          2. Volunteers allergic to ingredient of vaccine composition (can be checked from
             vaccination history), especially to egg

          3. History of progressive or severe neurologic disorder

          4. Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory
             difficulty, angioedema, or abdominal pain

          5. Known or suspected impairment/alteration of immune function, for example receiving
             immunosuppressive therapy or receiving blood, blood products and/or plasma derivatives
             or any parenteral immunoglobulin preparation

          6. Asthma that is unstable or required emergent care, hospitalization or intubation
             during the past two years or that required the use of oral or intravenous
             corticosteroids

          7. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or
             platelet disorder requiring special precautions) or significant bruising or bleeding
             difficulties with IM injections or blood draws

          8. History of thyroidectomy or thyroid disease that required medication within the past
             12 months

          9. Serious angioedema episodes within the previous 3 years or requiring medication in the
             previous two years

         10. Guillain-Barre Syndrome

         11. Self-reported seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B, or
             Hepatitis C

         12. Any other vaccines or immunoglobulin preparation within 1 weeks prior to enrollment

         13. Axillary temperature ≥ 38.0 degrees Celsius within 3 days of intended study
             vaccination

         14. Any conditions may influence the evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hunan Provincial Center of Disease Prevention and Control</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410005</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>April 7, 2011</study_first_submitted>
  <study_first_submitted_qc>April 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2011</study_first_posted>
  <last_update_submitted>September 8, 2018</last_update_submitted>
  <last_update_submitted_qc>September 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>H1N1</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

